Skip to the content
Please enable JavaScript in your browser to complete this form.
Country/ Region
*
[Please select]
Hong Kong
Macau
Japan
South Korea
Taiwan
Singapore
Others
Country/ Region_others
Title
*
[Please select]
Professor
Dr.
Mr.
Ms.
Others
Title_other
*
First name
*
Last name
*
Hospital / institute
*
Email address
*
Would you like to apply CME?
*
[Please select]
Yes
No
Full Name (please ensure your full/correct name for CME purposes)
*
CME Accreditation
*
[Please select]
The Hong Kong College of Pathologists
Hong Kong College of Physicians
Hong Kong College of Radiologists
The College of Surgeons of Hong Kong
Medical Council of Hong Kong
HCP registration number
*
1. When would you screen for KRAS G12C mutation for NSCLC patients?
*
At diagnosis (with other mutations)
At diagnosis (after screening EGFR, ALK, ROS1, PD-L1)
At first relapse
At second relapse
I don’t screen for KRAS G12C
2. What is the prevalence of KRAS G12C mutation in NSCLC in your practice?
*
~1% (~1 in 100)
~5% (~1 in 20)
~10% (~1 in 10)
~20% (~1 in 5)
Not sure
3. What are the top 2 treatment-related AEs you would be most concerned about when making treatment choice? (please select 2 options)
*
Fatigue
Diarrhea
Nausea
ALT/AST increase
QT prolongation
4. How likely will you prescribe sotorasib for KRAS G12C-mutated advanced NSCLC patients in 2L treatment?
*
Very likely
Likely
Not likely
Very unlikely
5. This education event was effective in meeting the learning objectives was set for this event.
*
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
6. How do you rate the overall quality of the event?
*
Excellent
Very Good
Good
Fair
Poor
7. I would recommend this educational event to my peers.
*
Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
HK-08602-LUM-2022-JUL. Approved: 2022-Jul